Table 1. Characteristics of patients... | American Society of Hematology

Table 1.

Characteristics of patients discordant for mutational status and ZAP-70 expression

CLL no.	Sex/Age, y	% IgVH*	IgVH gene	ZAP-70 mRNA†	% CD38⁺‡	Cytogenetics	Clinical course	Months to therapy
M1	M/66	92	4-59	(+)	8	+12	Stable	NE
M2	F/54	96	3-21	(+)	83	13q-	Stable	NE
M3	M/60	97	3-48	(+)	7	11q-	Treated	11
M4	M/82	95	3-21	(+)	18	Normal	Treated	20
U1	M/48	100	4-59	(-)	6	11q-	Treated	1
U2	F/80	100	2-70	(-)	45	+12	Treated	1
U3	F/70	100	3-33	(-)	7	Normal	Treated	51

CLL no.	Sex/Age, y	% IgVH*	IgVH gene	ZAP-70 mRNA†	% CD38⁺‡	Cytogenetics	Clinical course	Months to therapy
M1	M/66	92	4-59	(+)	8	+12	Stable	NE
M2	F/54	96	3-21	(+)	83	13q-	Stable	NE
M3	M/60	97	3-48	(+)	7	11q-	Treated	11
M4	M/82	95	3-21	(+)	18	Normal	Treated	20
U1	M/48	100	4-59	(-)	6	11q-	Treated	1
U2	F/80	100	2-70	(-)	45	+12	Treated	1
U3	F/70	100	3-33	(-)	7	Normal	Treated	51

+12 Indicates trisomy 12; 13q-, 13q deletion; 11q-, 11q deletion; NE, not evaluable.

Percentage of homology to germline IgVH gene.

As determined by microarray analysis.

Positivity (ie, staining above isotype control) by flow cytometry.